Study to Evaluate 13 Valent Pneumococcal Conjugate Vaccine (13vPnC) Vaccine Followed by 23-valent Pneumococcal Polysaccharide Vaccine (23vPS) Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients

NCT00980655 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

251

Enrollment

INDUSTRY

Sponsor class

Conditions

Vaccines, Pneumococcal Conjugate Vaccine

Interventions

BIOLOGICAL: 13vPnC
BIOLOGICAL: 23vPS

Sponsor

Pfizer